About
‘Diabetes is a chronic disease that affects hundreds of millions of people around the world. Clinical data support the recommendation that frequent monitoring of blood glucose levels is an important component of effective diabetes management which leads to reduction of risks of diabetes complications and HbA1c levels however, poor glucose monitoring compliance among people with type 2 diabetes is still of high prevalence. The invasiveness of the procedure is considered one of the major barriers.
Integrity applications have evolved from a spark of innovation of its founder, David Fragger, who had diabetes himself and was looking to overcome the hurdle of the invasiveness process and costs associated with monitoring his disease. Since the establishment of the company, its mission was to develop and democratize non-invasive glucose monitoring devices for home-use that are easy to use, convenient, and increase monitoring compliance by people with diabetes.
Years of clinical research and development have gathered into a unique combination of advanced algorithms and multiple non-invasive sensing technologies embedded in the only true non-invasive glucose monitoring device available in the market.’
Leadership Team
Management Team
David Malka
President, Co-Founder
Erez Ben-Zvi
Vice President Product
Shalom Shushan
Chief Technology Officer
Jolie Kahn
Chief Financial Officer
David Malka
President, Co-Founder
David Malka had served as Integrity’s Vice President of Operations since March 2012 until his promotion to President in November 2019. From 2003 to 2012, Mr. Malka was a director and Integrity’s Vice President of Operations. Prior to joining us, Mr. Malka served as a vice president of operations for Solid Systems from 2000 to 2003. From 1994 to 2000, Mr. Malka served as a manager of production and purchasing at Kollmorgen-Servotronix, an Israeli company specializing in the design, development and manufacture of digital servo control systems. From 1991 to 1993, Mr. Malka was a production design and inspection worker at TFL Time & Frequency Systems Ltd. Mr. Malka has a degree in practical engineering - industrial management from the Institute of Work & Production Productivity, Tel-Aviv and a Bachelor of Arts degree in management from the Open University in Israel.
Erez Ben-Zvi
Vice President Product
Erez brings 15 years of exceptional product management and leadership experience developing rapid growth strategies for medical device companies. Erez joins Integrity from 3D Systems Healthcare, a NASDAQ-listed 3D printing and digital manufacturing company where he spent 6 years in senior roles, including as Head of Global Market Development. In this role, Erez led all medical 3D printing and VR software solutions, designing the go-to-market strategy and overseeing global market development and expansion, as well as leading the product sales and growth at Point-of-Care. Previously, and until its acquisition by 3D Systems, Erez was leading the clinical application product portfolio at Simbionix, a leader in 3D virtual reality surgical simulation and training where he was responsible for the positioning and launch of their flagship patient-specific simulation product line. Prior to that, Erez held senior positions at Paieon Medical where he spearheaded commercialization of the company’s cardiac catheterization real-time navigation system and led the company through ISO certification and product applications to FDA, CE and Health Canada.
He holds a B.Tech degree in Industrial Engineering from Shenkar College of Engineering and Design, and an M.B.A from Bar-Ilan University
Shalom Shushan
Chief Technology Officer
Shalom Shushan has over 20 years of leadership experience in technology and product development, and extensive experience in sensor technologies, machine learning, algorithm design, and product portfolio strategy. He also has key technical expertise in consumer, safety, and medical device technologies, including a variety of health-related wearables. Shushan's leadership experience ranges from leading large international and cross-functional teams in various locations to working with and building emerging technology companies, including a medical device startup he founded. Most recently, Shushan was VP of Research and Development at Crow Technologies, Ltd. for 8 years where he drove the technical vision and strategy and was responsible for the development and implementation of the IoT, smart home and telemedicine platforms. Shalom Shushan was previously the co-founder and CEO of Nayos Ltd., a privately held integrated solutions company, and after its merger with Bio-Guard, CEO and CTO of Bio-Guard. Shalom Shushan holds a Bachelor of Science degree in electrical and computer engineering with a specialization in signal and image processing from Ben-Gurion University.
Jolie Kahn
Chief Financial Officer
Jolie Kahn has an extensive background in corporate finance and corporate and securities law. She has been the proprietor of Jolie Kahn, Esq. since 2002. Ms. Kahn has also acted in various corporate finance roles, including extensive involvement of preparation of period filings and financial statements and playing an integral part in public company audits. She also works with companies and hedge funds in complex transactions involving the structuring and negotiation of multi-million-dollar debt and equity financings, mergers, and acquisitions. Ms. Kahn has practiced law in the areas of corporate finance, mergers & acquisitions, reverse mergers, and general corporate, banking, and real estate matters. She represents both public and private companies, hedge funds, and other institutional investors in their role as investors in public companies. Ms. Kahn holds a BA from Cornell University and a J.D. magna cum laude from the Benjamin N. Cardozo School of Law.
Board of directors
Andrew G. Sycoff
Shimon D. Rapps
Dr. Robert Fischell
Allen E. Danzig
Andrew G. Sycoff
Andrew Sycoff has served as a Director of the Company since July 8, 2019, and is a member of the Nominating, Governance and Compensation Committee. Mr. Sycoff is the founder, Chief Executive Officer and Chairman of the Board of Andrew Garrett, Inc., a full-service investment bank providing wealth management and corporate advisory services, for which he has served as CEO and Chairman continuously since 1992. Client sectors include high net worth individuals and early to middle market stage companies. Mr. Sycoff holds Series 7 and 24 licenses. Mr. Sycoff has been actively investing in and advising companies for over 25 years and has extensive experience in the areas of securities brokerage, Capital Markets, Corporate Advisory and Mergers & Acquisitions. Mr. Sycoff previously served on the board of Brokerage America and Paragon Industries Corp., an electronics contract manufacturer. The Board has determined that Mr. Sycoff is suited to serve due to his extensive investment banking and public company experience.
Shimon D. Rapps
Shimon Rapps was appointed as a Director of the Company on July 31, 2019. He is also Chair of Integrity’s Audit Committee. Mr. Rapps serves as Head of Investment Banking at Andrew Garrett, Inc., a full-service investment bank providing wealth management and corporate advisory services, where he has been employed since early 2005. In this role, he oversees all of Andrew Garrett’s corporate finance, investment banking and corporate advisory activities. His experience spans equity and debt financings, mergers and acquisitions, private placements and IPO’s. He has extensive expertise with both public and private, emerging growth and middle market companies, and regularly advises CEO’s, CFO’s and Boards of Directors on matters of corporate governance and strategy. He holds the Series 7, 24, 63, and 66 licenses and is a Certified Public Accountant. The Board has determined that Mr. Rapps is suited to serve due to his extensive investment banking and public company experience.
Dr. Robert Fischell
Dr. Robert Fischell has served as one of Integrity’s directors since 2010. He also serves on Integrity’s Nominating, Governance and Compensation Committee. Dr. Fischell is an inventor and serial entrepreneur with over 160 issued U.S. patents. Starting in 1959, Dr. Fischell spent over 30 years with the Johns Hopkins University Applied Physics Laboratory, which resulted in 53 patents in both aerospace and biomedical technology. His interests at Johns Hopkins then turned to the invention of new medical devices such as pacemakers and implantable heart defibrillators. Starting in 1969, Dr. Fischell began the formation of 14 private companies that licensed his patents on medical devices. These companies include Pacesetter Systems, Inc. (purchased by Siemens and now part of St. Jude Medical, Inc.), IsoStent, Inc. (merged with Cordis Company, a Johnson and Johnson Company), NeuroPace, Inc., Neuralieve, Inc., Angel Medical Systems, Inc., and Svelte Medical Systems, Inc. As it relates to diabetes management devices, he was the inventor of the first implantable insulin pump (which became Minimed, which was sold to Medtronic). Dr. Fischell’s honors include Inventor of the Year for the USA in 1984, election to the National Academy of Engineering in 1989, the Distinguished Physics Alumnus Award of the University of Maryland, and several medals for distinguished accomplishments in science, engineering and innovation. In 2004, Discover magazine gave Dr. Fischell their annual Technology for Humanity award. In 2008, Dr. Fischell received the honorary degree of Doctor of Humane Letters from the Johns Hopkins University in recognition of his many lifesaving inventions. From June 2009 until March 2011, Dr. Fischell was a director of InspireMD, Inc. (OTCBB: NSPR), a medical device company focusing on the development and commercialization of its proprietary stent system, MGuard. Dr. Fischell received his BSME degree from Duke University and MS and Sc.D. degrees from the University of Maryland. At the White House on May 16, 2016, President Obama presented to Dr. Fischell the National Medical of Technology and Innovation, the highest award in the USA for achievements in innovative technology. The Board has determined that Dr. Fischell is suited to serve due to his extensive diabetes and medical device experience.
Allen E. Danzig
Allen Danzig has served on our Board since October 31, 2019 and is the Chair of our Nominating, Governance and Compensation Committee. Mr. Danzig most recently served as Vice President, Assistant General Counsel and Assistant Secretary of L3Harris Technologies, Inc., a global aerospace and defense technology contractor, with $17 billion in annual revenue. Prior to its merger with Harris Corporation in June 2019, Mr. Danzig served as Vice President, Assistant General Counsel and Assistant Secretary at L3 Technologies, Inc. where he had been employed since 2006. Prior to his employment at L3, Mr. Danzig served in management positions with Celanese Corporation, a global chemical and specialty materials company, and The Hertz Corporation, one of the world’s largest vehicle and equipment rental companies. He received his undergraduate degree from Adelphi University and law degree from Pace University School of Law and is a member of the New York State Bar. The Board has determined that Mr. Danzig is suited to serve due to his extensive legal and corporate governance experience.
Executive advisors
Yair Briman
Daniel McCaffrey
Yair Briman
Yair is a healthcare executive with over 25 years of experience. He currently serves as Chairman of the Board at Day Two, an Israeli based company that provides personalized nutrition empowering clinicians and people with diabetes manage glucose levels and improve overall health. Yair previously served as the global CEO of Healthcare Informatics at Philips, leading various digital health businesses, including HIS, EMR, PACS, Cardiology Informatics, Oncology Informatics, Interoperability, and Advanced Visualization. Prior to that, Yair served as the General Manager of the Advanced Visualization business unit at Philips. Yair was also the co-founder and board member of Sanara Venture, a healthcare investment platform backed by Philips & Teva. Previously, Yair served in key SW development and managerial roles at Intel.
Daniel McCaffrey
Dan is a published Behavioral Scientist (trained at the Harvard Medical School, National Institute of Health Fellow) with 10+ years of experience in digital health, medical devices and software as a medical device (SaMD). Dan is currently a Senior Product Manager at Samsung Health, focusing on enabling mobile technology to improve health and disease management through the development of digital therapeutics and remote monitoring. He focuses on using wearable technology, machine learning, artificial intelligence, NLP and IoT. Prior to that, Dan was the Director of Product Management for digital health, data and analytics at DexCom, developing the product vision, product strategy and product marketing of the Dexcom diabetes management software and Dexcom Electronic Health Record (EHR) integration product portfolios.
Press room
Investor Relations
Corporate policies
FAQs
32 HaMasger St.,
Tel Aviv, ISRAEL.
6201 15th Avenue, Brooklyn, NY 11219
333 Avenue of the Americas,
S.E. 2nd Avenue, Miami, FL 33131